Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Switzerland.
Medical Faculty of the University of Basel, Switzerland.
Clin Nutr. 2021 May;40(5):2762-2771. doi: 10.1016/j.clnu.2021.03.013. Epub 2021 Mar 15.
Patients with chronic kidney disease (CKD) are at substantial risk of malnutrition, which negatively affects clinical outcomes. We investigated the association of kidney function assessed at hospital admission and effectiveness of nutritional support in hospitalized medical patients at risk of malnutrition.
This is a secondary analysis of an investigator-initiated, randomized-controlled, Swiss multicenter trial (EFFORT) that compared individualised nutritional support with usual hospital food on clinical outcomes. We compared effects of nutritional support on mortality in subgroups of patients stratified according to kidney function at the time of hospital admission (estimated glomerular filtration rates [eGFR] <15, 15-29, 30-59, 60-89 and ≥ 90 ml/min/1.73 m).
We included 1943 of 2028 patients (96%) from the original trial with known admission creatinine levels. Admission eGFR was a strong predictor for the beneficial effects of nutritional support in regard to lowering of 30-day mortality. Patients with an eGFR <15, 15-29 and 30-59 had the strongest mortality benefit (odds ratios [95%CI] of 0.24 [0.05 to 1.25], 0.37 [0.14 to 0.95] and 0.39 [0.21 to 0.75], respectively), while patients with less severe impairment in kidney function had a less pronounced mortality benefits (p for interaction 0.001). A similar stepwise association of kidney function and response to nutritional support was found also for other secondary outcomes.
In medical inpatients at nutritional risk, admission kidney function was a strong predictor for the response to nutritional therapy. Initial kidney function may help to individualize nutritional support in the future by identification of patients with most clinical benefit.
Registered under ClinicalTrials.gov Identifier no. NCT02517476.
患有慢性肾脏病(CKD)的患者存在严重的营养不良风险,这会对临床结果产生负面影响。我们研究了入院时评估的肾功能与存在营养不良风险的住院内科患者营养支持的有效性之间的关系。
这是一项对瑞士多中心、研究者发起的、随机对照试验(EFFORT)的二次分析,该试验比较了个体化营养支持与常规医院饮食对临床结局的影响。我们根据入院时的肾功能(估计肾小球滤过率[eGFR]<15、15-29、30-59、60-89 和≥90ml/min/1.73m2)对患者进行分层,比较了营养支持对不同亚组患者死亡率的影响。
我们纳入了原始试验中已知入院肌酐水平的 2028 例患者中的 1943 例(96%)。入院 eGFR 是营养支持降低 30 天死亡率的有益效果的强有力预测因素。eGFR<15、15-29 和 30-59 的患者的死亡率获益最大(比值比[95%CI]分别为 0.24[0.05 至 1.25]、0.37[0.14 至 0.95]和 0.39[0.21 至 0.75]),而肾功能损害较轻的患者的死亡率获益则不那么显著(p 交互=0.001)。对于其他次要结局,也发现了肾功能与营养支持反应之间的类似逐步关联。
在存在营养风险的内科住院患者中,入院时的肾功能是营养治疗反应的一个强有力的预测因素。初始肾功能可能有助于通过识别具有最大临床获益的患者,为未来的营养支持个体化提供依据。
ClinicalTrials.gov 标识符:NCT02517476。